Pfizer has terminated the agreement to develop Daxas (roflumilast), a phosphodiesterase-IV inhibitor therapy for chronic obstructive pulmonary disease (COPD), following unimpressive results from a ...
WASHINGTON, May 18 (Reuters) - Shares of Forest Laboratories Inc rose 5.5 percent on Tuesday after the company announced a 50 million share buyback program and said regulators had not asked for ...
The National Institute for Health and Care Excellence has rejected AstraZeneca's Daxas for use by the NHS in certain patients with chronic obstructive pulmonary disease (COPD). The National Institute ...
- Data show reductions in moderate and severe exacerbations requiring medical intervention - Application for marketing authorisation in EU and US expected in 2009 - Partnering process for ...
July 21, 2010 — The European Commission (EC) has approved roflumilast once-daily tablets (Daxas; Nycomed, Inc) as an add-on to bronchodilator therapy for the maintenance treatment of severe chronic ...
LONDON (Reuters) - Private Swiss drug company Nycomed is ready for a stock market float in 2009, if market conditions improve, after reporting positive clinical data with its experimental lung drug ...
Nycomed is in luck. The European Medicines Agency today recommended approval of Daxas, the company's once-a-day pill for patients with severe COPD. The approval follows an expert FDA panel's decision ...
A new drug could offer hope to thousands of people suffering with a chronic lung disease in the Black Country and Staffordshire - but only if doctors ask for it. Published Oct 11, 2010 A new drug ...
AstraZeneca’s Daxas is now likely to be routinely available on the NHS to patients with chronic obstructive pulmonary disease (COPD), after new evidence helped persuade cost regulators that the drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results